Drug Trial Radar · NCT07245368
Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Nov 4, 2025
Primary completion
Oct 1, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Prana Therapies IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.
Conditions
- Mild to Moderate Asthma
Interventions
PRA-216Drug
biologic
PlaceboDrug
matching placebo for PRA-216
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) with a single dose of PRA-216 in healthy volunteers (SAD arm)Time frame: Up to Study Day 169
- Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) of multiple doses of PRA-216 in healthy volunteers (MAD arm)Time frame: up to Study Day 169
- Phase 2a: To evaluate the effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in asthma participantsTime frame: Up to Study Day 57
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Emertitus Research Sydney
Botany, New South Wales, Australia · Recruiting
Emeritus Research Camberwell
Camberwell, Victoria, Australia · Recruiting
Monash Health
Clayton, Victoria, Australia · Not yet recruiting
Linear
Joondalup, Western Australia, Australia · Recruiting
Linear
Nedlands, Western Australia, Australia · Recruiting
PCRN Waikato, Nawton
Hamilton, Auckland, New Zealand · Recruiting
Pacific Clinical Research Network-Auckland
Takapuna, Auckland, New Zealand · Recruiting
PCRN Wellington, Ebdentown
Upper Hutt, Auckland, New Zealand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.